GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Replek AD (XMAE:REPL) » Definitions » Beneish M-Score

Replek AD (XMAE:REPL) Beneish M-Score : -0.88 (As of Mar. 28, 2025)


View and export this data going back to . Start your Free Trial

What is Replek AD Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.88 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Replek AD's Beneish M-Score or its related term are showing as below:

XMAE:REPL' s Beneish M-Score Range Over the Past 10 Years
Min: -3.02   Med: -2.68   Max: 21.27
Current: -0.88

During the past 13 years, the highest Beneish M-Score of Replek AD was 21.27. The lowest was -3.02. And the median was -2.68.


Replek AD Beneish M-Score Historical Data

The historical data trend for Replek AD's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Replek AD Beneish M-Score Chart

Replek AD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.84 -2.94 -2.68 21.27 -0.88

Replek AD Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 21.27 - - -0.88

Competitive Comparison of Replek AD's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Replek AD's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Replek AD's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Replek AD's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Replek AD's Beneish M-Score falls into.


;
;

Replek AD Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Replek AD for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 2.1321+0.528 * 1.0961+0.404 * 1.5135+0.892 * 1.2272+0.115 * 0.5902
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * 0.005694-0.327 * 1.1795
=-0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was MKD470 Mil.
Revenue was MKD1,948 Mil.
Gross Profit was MKD469 Mil.
Total Current Assets was MKD1,083 Mil.
Total Assets was MKD3,308 Mil.
Property, Plant and Equipment(Net PPE) was MKD1,489 Mil.
Depreciation, Depletion and Amortization(DDA) was MKD112 Mil.
Selling, General, & Admin. Expense(SGA) was MKD0 Mil.
Total Current Liabilities was MKD757 Mil.
Long-Term Debt & Capital Lease Obligation was MKD184 Mil.
Net Income was MKD224 Mil.
Gross Profit was MKD0 Mil.
Cash Flow from Operations was MKD205 Mil.
Total Receivables was MKD180 Mil.
Revenue was MKD1,587 Mil.
Gross Profit was MKD419 Mil.
Total Current Assets was MKD980 Mil.
Total Assets was MKD2,918 Mil.
Property, Plant and Equipment(Net PPE) was MKD1,509 Mil.
Depreciation, Depletion and Amortization(DDA) was MKD65 Mil.
Selling, General, & Admin. Expense(SGA) was MKD54 Mil.
Total Current Liabilities was MKD605 Mil.
Long-Term Debt & Capital Lease Obligation was MKD98 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(469.831 / 1948.035) / (179.562 / 1587.371)
=0.241182 / 0.113119
=2.1321

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(418.681 / 1587.371) / (468.771 / 1948.035)
=0.263757 / 0.240638
=1.0961

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1082.815 + 1488.683) / 3308.062) / (1 - (980.278 + 1508.753) / 2918.352)
=0.222657 / 0.147111
=1.5135

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1948.035 / 1587.371
=1.2272

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(65.019 / (65.019 + 1508.753)) / (112.06 / (112.06 + 1488.683))
=0.041314 / 0.070005
=0.5902

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 1948.035) / (54.395 / 1587.371)
=0 / 0.034267
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((183.669 + 756.506) / 3308.062) / ((98.067 + 605.13) / 2918.352)
=0.284207 / 0.240957
=1.1795

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(224.195 - 0 - 205.36) / 3308.062
=0.005694

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Replek AD has a M-score of -0.88 signals that the company is likely to be a manipulator.


Replek AD Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Replek AD's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Replek AD Business Description

Traded in Other Exchanges
N/A
Address
Kozle 188, Skopje, MKD
Replek AD is engaged in the development, design and production of generic medicines. The company develops drugs in different pharmaceutical therapeutic categories including anti-platelet, lipid-lowering, atypical antipsychotic, anti-infective, among others. It manufactures drugs in different forms including tablets, capsules, oral solutions, creams and ointments. Its product portfolio consists of Clopidogrel, Atorvastatin, Simvastatin, risperidone, Clarythromycin, Ciprofloxacin, Meloksikam, Risperidon, terazosin, among others. Replek also offers cannabis oil products, food supplements and cosmetics.